Public Employees Retirement System of Ohio continued to hold its position in Incyte Corporation (NASDAQ:INCY) during the first quarter, Holdings Channel reports. The institutional investor owned 101,186 shares of the biopharmaceutical company’s stock at the end of the first quarter. Public Employees Retirement System of Ohio’s holdings in Incyte Corporation were worth $13,526,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of INCY. Tower Research Capital LLC TRC acquired a new position in shares of Incyte Corporation during the first quarter valued at about $105,000. FNY Partners Fund LP raised its position in shares of Incyte Corporation by 4,825.0% in the first quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 965 shares in the last quarter. IFP Advisors Inc raised its position in shares of Incyte Corporation by 6.8% in the first quarter. IFP Advisors Inc now owns 1,043 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 66 shares in the last quarter. Howard Hughes Medical Institute raised its position in shares of Incyte Corporation by 42.2% in the first quarter. Howard Hughes Medical Institute now owns 1,210 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 359 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its position in shares of Incyte Corporation by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 22 shares in the last quarter. Institutional investors own 92.79% of the company’s stock.
Shares of Incyte Corporation (INCY) traded up 0.219% during midday trading on Tuesday, hitting $134.965. The stock had a trading volume of 347,547 shares. Incyte Corporation has a 52 week low of $71.75 and a 52 week high of $153.15. The company’s 50 day moving average is $124.12 and its 200 day moving average is $123.48. The firm’s market cap is $27.64 billion.
Incyte Corporation (NASDAQ:INCY) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.97) by $0.01. The company had revenue of $384.08 million for the quarter, compared to analysts’ expectations of $359.19 million. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. Incyte Corporation’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.12 earnings per share. On average, equities analysts predict that Incyte Corporation will post ($0.72) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Public Employees Retirement System of Ohio Has $13,526,000 Position in Incyte Corporation (INCY)” was first reported by sleekmoney and is owned by of sleekmoney. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://sleekmoney.com/public-employees-retirement-system-of-ohio-has-13526000-position-in-incyte-corporation-incy/1943733.html.
Several equities analysts recently issued reports on INCY shares. Nomura started coverage on Incyte Corporation in a research report on Wednesday, March 1st. They issued a “buy” rating for the company. Instinet started coverage on Incyte Corporation in a research report on Wednesday, March 1st. They issued a “buy” rating and a $148.00 price objective for the company. Cowen and Company reiterated an “outperform” rating on shares of Incyte Corporation in a research report on Wednesday, March 8th. William Blair started coverage on Incyte Corporation in a research report on Tuesday, March 21st. They issued an “outperform” rating for the company. Finally, Zacks Investment Research upgraded Incyte Corporation from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 22nd. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $141.93.
In related news, Director Jean Jacques Bienaime bought 500 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were bought at an average price of $115.00 per share, with a total value of $57,500.00. Following the completion of the transaction, the director now directly owns 4,177 shares in the company, valued at $480,355. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David W. Gryska sold 41,528 shares of Incyte Corporation stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $138.00, for a total value of $5,730,864.00. Following the transaction, the insider now directly owns 20,754 shares in the company, valued at approximately $2,864,052. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 3,500 shares of company stock worth $464,670 and have sold 119,427 shares worth $15,782,469. 13.70% of the stock is owned by insiders.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/public-employees-retirement-system-of-ohio-has-13526000-position-in-incyte-corporation-incy/1943733.html
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.